ADMS Adamas Pharmaceuticals NASDAQ $8.22 intraday: Oversold bounce trade setup
We see ADMS stock trading at $8.22 intraday on the NASDAQ with a relVolume of 2.35, signaling a possible oversold bounce setup. Volume today is 3,151,400 versus an average of 1,338,689, and the 50-day average price sits at 6.9972. The stock’s 52-week range is $4.02–$9.15, and the short-term technicals show tight intraday price action between $8.18 and $8.25. For traders using an oversold bounce strategy, this setup pairs heavier-than-normal trading with clear valuation and catalyst risk in the healthcare sector
ADMS stock intraday snapshot and key metrics
Adamas Pharmaceuticals, Inc. (ADMS) is trading on NASDAQ in USD at $8.22 with a day low of $8.18 and a day high of $8.25. Volume is 3,151,400, above the average of 1,338,689, and relative volume is 2.35, suggesting above-normal intraday interest. The 50-day average price is 6.9972 and the 200-day average is 5.5538, showing the stock has recovered well from the $4.02 low.
Why the oversold bounce matters for ADMS stock
The oversold bounce thesis rests on quick mean reversion after heavy selling and a strong rebound in volume. ADMS’s high relative volume and price sitting below recent resistance near the $9.15 year high create a tactical entry window. Traders should watch intraday range and the Keltner channel middle at $8.22 as a trigger level.
Technical indicators, triggers, and Meyka AI grade for ADMS stock
Technical signals are mixed but actionable for short-term traders. ATR is 0.07, Keltner Channels read Upper 8.36 / Middle 8.22 / Lower 8.08, and momentum oscillators show neutral readings. Meyka AI rates ADMS with a score out of 100: Score 62.36 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus.
Fundamentals and valuation context for ADMS stock
Adamas operates in Healthcare, Drug Manufacturers – Specialty & Generic, with cash per share 2.37 and net income per share -1.63. EV/Revenue is 0.78 and trailing PE is negative -5.04, reflecting losses. The company reports a current ratio of 3.20, indicating short-term liquidity, while operating cash flow per share is -1.44, showing cash burn that investors must monitor.
Catalysts, price targets, and ADMS stock forecast
Near-term catalysts include clinical readouts around ADS-5102 and commercial performance of GOCOVRI and Namzaric. Meyka AI’s forecast model projects a monthly target of $9.10 and a one-year target of $15.04. We present a tactical intraday target at $9.10 and a mid-term target range $12.50–$15.04, while noting these are model-based projections and not guarantees.
Risks, sector outlook, and a practical trade plan for ADMS stock
Key risks include clinical trial outcomes, reimbursement pressure, and inventory dynamics—days of inventory on hand is extremely high at 1306.33 days. The healthcare sector shows steady interest in specialty drugs, but regulatory and commercial execution risks remain. For an oversold bounce strategy, we suggest a tight stop under $7.60, partial profit at $9.10, and review at $12.50 using position sizing aligned with your risk limit.
Final Thoughts
ADMS stock is forming an intraday oversold bounce setup with price at $8.22, high relative volume (2.35), and clear short-term resistance near $9.10–$9.15. Meyka AI’s forecast model projects a one-year target of $15.04, implying an upside of 82.90% from the current price, and a monthly target of $9.10, implying 10.73% upside. Meyka AI rates ADMS 62.36 out of 100 (Grade B, HOLD), a view that weighs sector comparison, financial growth, and analyst inputs. Traders using an oversold bounce plan should combine tight risk controls, watch clinical catalysts, and verify liquidity—volume today is 3,151,400. Forecasts are model-based projections and not guarantees. For more details, see the Meyka stock page for ADMS and the latest market commentary from Seeking Alpha and Investing.com source source and our ADMS market hub at Meyka ADMS. Meyka AI provided the AI-powered market analysis used here.
FAQs
Is ADMS stock a buy on this oversold bounce today?
ADMS stock may offer a tactical buy for short-term traders if price holds above $8.00 and volume remains elevated. Use tight stops and small position sizes. This is not financial advice.
What are the key fundamental risks for ADMS stock?
Principal risks include clinical trial outcomes, reimbursement pressure, and elevated inventory days (1306.33). Cash burn and negative operating cash flow per share (-1.44) also matter.
How does Meyka AI forecast ADMS stock performance?
Meyka AI’s forecast model projects $9.10 monthly and $15.04 one year for ADMS stock. These are model-based projections and not guarantees; we show implied upside versus the current $8.22 price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
